12th Gilead Biomedical Research Grants Launch with Expanded Focus on HIV Prevention

María Río, Vice President and General Manager of Gilead Sciences Spain and Portugal , and Marina Pollán, Director of the Carlos III Health Institute (ISCIII), an agency under the Ministry of Science, Innovation and Universities, today formalized the signing of the collaboration agreement for the 12th Gilead Biomedical Research Grants Call for HIV, Hemato- Oncology and Medical Oncology.

This scholarship program, created to promote biomedical research and support scientific talent in areas with unmet medical needs, has established itself over time as the most important biomedical R&D program promoted by a pharmaceutical company in Spain. As every year, the ISCIII will coordinate the independent evaluation of the projects submitted to the scholarship program.

Gilead expands research grants to include HIV prevention, boosting support for high-impact biomedical projects in Spain

This new edition includes, for the first time, a research line that will evaluate research projects on improving access to and implementation of PrEP. This is a strategic and priority line of work to advance toward controlling the epidemic and respond to a growing need identified by both the scientific community and the most vulnerable people.

“It is a tremendous satisfaction to announce the twelfth edition of the Gilead Biomedical Research Fellowships and, with it, continue to promote quality research in Spain. This year, in addition to focusing on HIV, Hemato-Oncology, and Medical Oncology, as has been the case in recent years, we are expanding its scope to include new lines of work such as HIV prevention.”

“With this, we aim to promote projects that benefit patients and society at large. The collaboration of the Carlos III Health Institute undoubtedly gives prestige to this event and decisively contributes to its status as the most important biomedical R&D event organized by a pharmaceutical company in our country,” stated María Río, Vice President and General Manager of Gilead Spain and Portugal.

Marina Pollán, director of the ISCIII, pointed out, “As the leading public health research organization, we believe it is essential to continue supporting public-private collaboration initiatives, such as this one, in which the ISCIII has been supporting Gilead for years. The Institute’s participation in the evaluation of these grant projects allows us to continue consolidating our commitment to generating scientific knowledge and further achieving our common goal: facilitating scientific advancement to improve people’s health.”

With over a decade of experience, the Gilead Biomedical Research Grants have established themselves as the most significant research award sponsored by a pharmaceutical company in Spain, both in terms of their scope and impact. Each year, they allocate nearly one million euros to promote projects of high scientific value, having already supported 203 research projects in 13 autonomous communities.

This initiative is possible thanks to the close collaboration between Gilead Sciences and the Carlos III Health Institute, an entity that guarantees a rigorous, transparent, and independent evaluation process, ensuring that the selected projects meet the highest standards of scientific quality and clinical relevance. The evaluation of

The projects will be carried out by the Carlos III Health Institute’s network of external evaluators, which guarantees independence in the decision

Furthermore, this twelfth edition—for the fifth consecutive year—will award special recognition to papers presented by young researchers. This is an initiative through which Gilead and the ISCIII seek to highlight the research work and foster the experience and talent of young Spanish scientists in various areas with unmet medical needs.

Applications for the Gilead Biomedical Research Grants must be submitted in English by Monday, June 30. Only one research project may be submitted, and a maximum of two projects will be allowed per therapeutic area and healthcare center to which the principal investigator (PI) is affiliated. The Carlos III Health Institute will then be responsible for reviewing the projects and compiling the priority list.

__

(Featured image by CDC via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us